OPKO Health Inc (NASDAQ: OPK) is a healthcare company that operates pharmaceutical and diagnostics businesses across multiple countries. Revenue comes from pharmaceutical product sales and royalties, including a tiered gross profit share from NGENLA (Somatrogon) commercialized by Pfizer in over 50 global markets, sales of Rayaldee in the United States, and pharmaceutical operations in Spain, Ireland, Chile, and Mexico. The diagnostics segment operates through BioReference Health, LLC, a clinical laboratory focused on core clinical testing and specialty urology services in New York and New Jersey following divestitures of non-core laboratory assets in 2024 and 2025 for total aggregate consideration of up to $462.5 million. OPKO manages two reportable segments: pharmaceuticals and diagnostics. The pharmaceutical segment spans operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, and the United States. Irish subsidiary EirGen Pharma specializes in high-potency oral solid dose pharmaceutical products exported to over 60 countries. Subsidiary ModeX Therapeutics develops multi-specific immune therapies in oncology, immunology, and infectious diseases.

Revenue model

Tiered gross profit share from Pfizer's commercialization of NGENLA (Somatrogon); pharmaceutical product sales in Spain, Ireland, Chile, and Mexico; Rayaldee prescription sales in the United States; clinical laboratory testing fees through BioReference Health in New York and New Jersey; licensing and collaboration agreements.

Products and services

NGENLA (Somatrogon), a growth hormone therapy commercialized by Pfizer; Rayaldee, a pharmaceutical product sold in the United States; EirGen Pharma high-potency oral solid dose pharmaceutical products exported to over 60 countries; BioReference Health clinical laboratory testing services, specialty urology diagnostics, and women's health testing in New York and New Jersey; 4Kscore test for urology; ModeX Therapeutics pipeline including MDX2001 tetraspecific antibody (Phase 1 trial at fifth dose level as of October 2025) and MDX2003 tetraspecific antibody (preclinical stage in 2025, Phase 1 expected in early 2026).

Customers and end markets

Patients and physicians in clinical laboratory testing; urology and women's health specialties in New York and New Jersey; third-party payors and state and multi-state programs for diagnostic services; global pharmaceutical markets through Pfizer partnership for NGENLA; international pharmaceutical markets via established operations in Spain, Ireland, Chile, Mexico, Ecuador, France, and Israel.

Value-chain role

Drug developer and licensor (NGENLA partnered with Pfizer for commercialization); pharmaceutical manufacturer and distributor through regional subsidiaries; clinical laboratory operator for specialty diagnostic testing.

Geographic exposure

United States (BioReference diagnostics in New York and New Jersey; Rayaldee sales); Spain, Ireland, Chile, Mexico, Ecuador, France, and Israel (pharmaceutical operations); EirGen Pharma exports to over 60 countries; NGENLA commercialized across more than 50 global markets by Pfizer.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: 23ANDME HOLDING CO. Addus Homecare Corp AGILITI, INC. \DE Astrana Health Inc CVS Health Corp Pediatrix Medical Group Inc ModivCare Inc